New hope for lung transplant patients: drug may block dangerous virus
NCT ID NCT05041426
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug letermovir to prevent CMV infection in 15 adults who had a lung transplant for idiopathic pulmonary fibrosis (IPF). Participants took letermovir daily for 6 or 12 months depending on their CMV risk. The goal was to see if the drug could prevent CMV infection during and shortly after treatment. This was a small pilot study with no comparison group, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Letermovir (also known as Prevymis)
What this could lead to
If it works, this could offer a safer way to prevent CMV infection after lung transplant, reducing side effects like low white blood cell counts.
What could go wrong
This is a small pilot study with only 15 participants and no control group, so results may not apply broadly. The drug may still cause side effects or fail to prevent CMV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC
Pittsburgh, Pennsylvania, 15213, United States